Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
NCT07327489
This study is recruiting at 6 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
This study will collect tumor specimens with correlated clinical and demographic data from patients who are undergoing a biopsy or similar procedure to obtain tumor tissue as a normal course of their medical management or diagnostic work-up for suspected or confirmed cancer.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Cancer
- Immunotherapy
- Advanced Solid Tumors Cancer
- Bladder Cancer
- TNBC, Triple Negative Breast Cancer
- Colorectal Cancer
- DMMR Colorectal Cancer
- MSI-H Colorectal Cancer
- Endometrial Cancer
- Head and Neck Cancer
- Kidney Cancer
- Liver Cancer
- NSCLC (Non-small-cell Lung Cancer)
- Skin Cancer
- Melanoma (Skin Cancer)
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Elephas
- Last updated on ClinicalTrials.gov
- June 29, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arkansas · 1
- Mercy Hospital - FTS · Fort Smith, AR
Maryland · 1
- Frederick Health Hospital · Frederick, MD
Missouri · 3
- Mercy Hospital - SPG · Springfield, MO
- Mercy Hospital - South · St Louis, MO
- Mercy Hospital -STL · St Louis, MO
Oklahoma · 1
- Mercy Hospital - OKC · Oklahoma City, OK
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.